Stockreport

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications [Yahoo! Finance]

IO Biotech, Inc.  (IOBT) 
PDF Five-year analysis of median progression free survival was 25.5 months These results reinforce the potential of immune-modulatory vaccination NEW YORK, Dec. 15, 202 [Read more]